PaulAnh VietPhamMD

PubMed

• 202 citations
  Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious D...
  Gregory M. Lucas, Michael W. Ross, Peter G. Stock, Michael G. Shlipak, Christina M. Wyatt, Samir K. Gupta, Mohamed G. Atta, Kara Wools-Kaloustian, Paul A. Pham, Leslie...> ;Clinical Infectious Diseases. 2014 Nov 1
• Authors' reply.
  Hsu AJ, Yung R, Pham PA> ;Pharmacotherapy. 2013-05-01
• Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
  Lee LSU, Pham P, Flexner C> ;Ann. Acad. Med. Singap.. 2012-12-01
• Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth.
  Wong FL, Hsu AJ, Pham PA, Siberry GK, Hutton N, Agwu AL> ;Pediatr. Infect. Dis. J.. 2012-12-01
• Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults.
  Yehia BR, Mehta JM, Ciuffetelli D, Moore RD, Pham PA, Metlay JP, Gebo KA> ;Clin. Infect. Dis.. 2012-08-01
• Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population.
  Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA> ;AIDS. 2012-07-31
• Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy.
  Hsu AJ, Carson KA, Yung R, Pham PA> ;Pharmacotherapy. 2012-06-01
• 24 citations
  Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
  David L. Thomas, John G. Bartlett, Marion G. Peters, Kenneth E. Sherman, Mark S. Sulkowski, Paul A. Pham> ;Clinical Infectious Diseases. 2012 Apr 1
• Emerging antiretroviral drug interactions.
  Pham, P. A.,Flexner, C.> ;J. Antimicrob. Chemother.. 2010 Dec 07
• Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
  Jenh AM, Pham PA> ;Expert Rev Anti Infect Ther. 2010-10-01
• 9 citations
  Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy V...
  Gaik Hong Soon, Ping Shen, Eu Leong Yong, Paul A. Pham, Charles Flexner, Lawrence Lee> ;Antimicrobial Agents and Chemotherapy. 2010 Jul 1
• HIV infection-related tuberculosis: clinical manifestations and treatment.
  Sterling, T.R., Pham, P.A., Chaisson, R.E.> ;Clin Infect Dis. 2010 May 15
• Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
  Lee LS, Soon GH, Shen P, Yong E, Flexner C, Pham P> ;Antivir. Ther. (Lond.). 2010-01-01
• Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
  Pham, P. A.,la Porte, C. J.,Lee, L. S.,van Heeswijk, R.,Sabo, J. P.,Elgadi, M. M.,Piliero, P. J.,Barditch-Crovo, P.,Fuchs, E.,Flexner, C.,Cameron, D. W.> ;Antimicrob. Agents Chemother.. 2009 Aug 12
• Tenofovir for the treatment of hepatitis B virus.
  Jenh, A.M., Thio, C.L., Pham, P.A.> ;Pharmacotherapy. 2009-10-01
• Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression.
  Pham, P.A.> ;AIDS Patient Care STDS. 2009-10-01
• 14 citations
  Drug-drug interaction programs in clinical practice.
  P A Pham> ;Clinical Pharmacology and Therapeutics. 2008 Mar 1
• Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
  Pham, P.A., Flexner, C., Parsons, T., Vasist, L., Fuchs, E., Carson, K., Agarwala, S., Barditch-Crovo, P.> ;J Acquir Immune Defic Syndr. 2007 Jun 1
• 6 citations
  Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz:
  Paul A. Pham, Craig W. Hendrix, Patricia Barditch-Crovo, Teresa L. Parsons, Wasif A. Khan, Michelle Parish, Christine Radebaugh, Kathryn A. Carson, Gary E Pakes, Roula...> ;Antiviral Therapy. 2007 Aug 1
• Drug profile: telbivudine (Tyzeka).
  Pham, P.A., Thio, C.> ;Hopkins HIV Rep. 2007 Jan
• Expanded drug access: etravirine (formerly TMC-125).
  Colquitt, A.R., Pham, P.A.> ;Hopkins HIV Rep. 2007 Jan
• Expanded access drug profile: raltegravir (RAL, MK-0518).
  Colquitt, A.R., Pham, P.A.> ;Hopkins HIV Rep. 2007 Jan
• New York state recommendations for drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs--a summary.
  Paul Pham, Richard W. Dunning> ;The Hopkins HIV Report. 2005 Nov 1
• FDA approves Aptivus (tipranavir).
  Pham, P.A.> ;Hopkins HIV Rep. 2005 Jul
• Drug profile: fosamprenavir (Lexiva).
  Pham, P.A.> ;Hopkins HIV Rep. 2003 Nov
• Join now to see all